1620 related articles for article (PubMed ID: 19200817)
1. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
2. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
3. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.
Navabi H; Jasani B; Reece A; Clayton A; Tabi Z; Donninger C; Mason M; Adams M
Vaccine; 2009 Jan; 27(1):107-15. PubMed ID: 18977262
[TBL] [Abstract][Full Text] [Related]
4. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
5. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
[TBL] [Abstract][Full Text] [Related]
6. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.
Navabi H; Croston D; Hobot J; Clayton A; Zitvogel L; Jasani B; Bailey-Wood R; Wilson K; Tabi Z; Mason MD; Adams M
Blood Cells Mol Dis; 2005; 35(2):149-52. PubMed ID: 16061407
[TBL] [Abstract][Full Text] [Related]
7. Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3.
Kulka M; Alexopoulou L; Flavell RA; Metcalfe DD
J Allergy Clin Immunol; 2004 Jul; 114(1):174-82. PubMed ID: 15241362
[TBL] [Abstract][Full Text] [Related]
8. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
10. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses.
Bohnenkamp HR; Papazisis KT; Burchell JM; Taylor-Papadimitriou J
Cell Immunol; 2007 Jun; 247(2):72-84. PubMed ID: 17927969
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy.
Nicodemus CF; Wang L; Lucas J; Varghese B; Berek JS
Am J Obstet Gynecol; 2010 Jun; 202(6):608.e1-8. PubMed ID: 20080226
[TBL] [Abstract][Full Text] [Related]
13. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer.
Seya T; Akazawa T; Uehori J; Matsumoto M; Azuma I; Toyoshima K
Anticancer Res; 2003; 23(6a):4369-76. PubMed ID: 14666723
[TBL] [Abstract][Full Text] [Related]
14. Polyinosinic-polycytidylic acid-mediated stimulation of human gammadelta T cells via CD11c dendritic cell-derived type I interferons.
Kunzmann V; Kretzschmar E; Herrmann T; Wilhelm M
Immunology; 2004 Jul; 112(3):369-77. PubMed ID: 15196204
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).
Adams M; Navabi H; Jasani B; Man S; Fiander A; Evans AS; Donninger C; Mason M
Vaccine; 2003 Jan; 21(7-8):787-90. PubMed ID: 12531360
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
17. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines: challenges and outlook in the field.
Paul S; Acres B; Limacher JM; Bonnefoy JY
IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.
Salucci V; Mennuni C; Calvaruso F; Cerino R; Neuner P; Ciliberto G; La Monica N; Scarselli E
Scand J Immunol; 2006 Jan; 63(1):35-41. PubMed ID: 16398699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
